MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY Journal
Overview
publication venue for
- Recommended measurement instruments for genitourinary symptoms associated with menopause: the COMMA (Core outcomes in menopause) consortium. 31:591-599. 2024
- Recommended measurement instruments for menopausal vasomotor symptoms: the COMMA (Core Outcomes in Menopause) consortium. 31:582-590. 2024
- Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert. 28:998-1003. 2021
- A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. 28:852-858. 2021
- Medroxyprogesterone opposes estradiol-induced renal damage in midlife ovariectomized Long Evans rats. 27:1420-1424. 2020
- Biocompatibility and zinc release testing of a zinc-containing vaginal gel.. 27:143-149. 2020
- Cervicovaginal lavage fluid zinc level as a marker of vaginal atrophy. 2020
- Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. 26:611-621. 2019
- Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women. 25:762-766. 2018
- A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. 25:133-138. 2018
- Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. 25:1339-1353. 2018
- Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial. 24:1003-1010. 2017
- TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. 24:510-516. 2017
- The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. 24:409-416. 2017
- Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. 24:1246-1256. 2017
- Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. 24:1167-1174. 2017
- Prescribing of FDA-approved and compounded hormone therapy differs by specialty. 23:1075-1082. 2016
- Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. 23:243-256. 2016
- Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data. 23:957-964. 2016
- Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertension. 22:1067-1075. 2015
- Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). 22:950-963. 2015
- Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. 22:36-43. 2015
- Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. 22:1289-1295. 2015
- Differential effects of menopausal therapies on the endometrium. 21:899-908. 2014
- Vaginal cytokines do not differ between postmenopausal women with and without symptoms of vulvovaginal irritation. 21:840-845. 2014
- A randomized, double- blind, placebo- controlled study of the lowest effective dose of drospirenone with 17 beta- estradiol for moderate to severe vasomotor symptoms in postmenopausal women. 21:227-235. 2014
- Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17 beta-estradiol in postmenopausal women with moderate to severe vasomotor symptoms. 21:236-242. 2014
- Reproductive history and postmenopausal rheumatoid arthritis among women 60 years or older: Third National Health and Nutrition Examination Survey. 20:930-935. 2013
- Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. 20:47-56. 2013
- Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. 20:38-46. 2013
- Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. 19:622-629. 2012
- Endometrial bleeding in postmenopausal women: with and without hormone therapy. 18:416-420. 2011
- Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. 16:1102-1108. 2009
- Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. 16:1109-1115. 2009
- Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. 16:923-931. 2009
- Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. 16:907-922. 2009
- Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. 16:897-906. 2009
- Nocturia and hormone therapy: impact on sleep? 2021
- Ospemifene: less venous thrombosis than other selective estrogen receptor modulators in postmenopausal women with vulvo vaginal atrophy 2020
- Pelvic organ prolapse: from estrogen to pessary 2019
- Menopausal hormone therapy for primary prevention: why the USPSTF is wrong 2017
- Vaginal atrophy and disease susceptibility: the role of leukocytes 2015
- Delivery of therapeutic agents to the target tissue 2011
- The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women 2011
- A simple inexpensive screening test for endometrial abnormalities in asymptomatic women using tamoxifen 2010
- Drospirenone, a progestin with added value for hypertensive postmenopausal women 2007
- Progestogens: effects on clinical and biochemical parameters in postmenopausal women 2005
- Untitled 2018
- Untitled 2018
- LETTERS TO THE EDITOR Reply 2017
- LETTERS TO THE EDITOR Reply 2017
- Untitled 2016
- Impact of Travel Time to Menopausal Follow Up Care, Symptom Burden, and Acceptance of Hormone Therapy 2023
- Self-Reported Efficacy of Hormone Therapy and Symptom Burden in Menopausal Patients with Obesity 2023
- Endometrial Progesterone Receptor Expression with Softgel Vaginal Estradiol (4-mu g or 10-mu g) Inserts 2021
- Literature Review of Hormone Therapy ( HT) Containing Estradiol or Progesterone vs HT Containing Other Estrogens or Progestogens 2021
- Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System (SA/EE; CVS): An Option That May Be Suitable For Perimenopausal Women 2020
- The Effects of a 17 beta-estradiol, Softgel, Vaginal Insert on Vulvar and Vaginal Atrophy (VVA), Including Moderate to Severe Dyspareunia and Vaginal Dryness in Postmenopausal Women > 60 Years of Age 2020
- Effect of Estradiol and Progesterone on Cervico-Vaginal Cytokines in Premenopausal and Postmenopausal Women 2019
- Uterine Bleeding Rates with Hormone Therapies in Menopausal Women with Vasomotor Symptoms 2019
- Effects of Single-Capsule 17 beta-Estradiol/Progesterone (TX-001HR) on Weight and Blood Pressure in Menopausal Women of the REPLENISH Trial 2018
- Effects of Single-Capsule 17 beta-Estradiol/Progesterone (TX-001HR) on Weight and Blood Pressure in Menopausal Women of the REPLENISH Trial 2018
- Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness: A phase 3, Randomized Double-Blind Placebo-Controlled Multicenter Clinical Trial 2018
- Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness: A phase 3, Randomized Double-Blind Placebo-Controlled Multicenter Clinical Trial 2018
- 17 beta-Estradiol/Progesterone in a Single Oral Softgel Capsule (TX-001HR) Significantly Reduced Moderate-to-Severe Vasomotor Symptoms without Endometrial Hyperplasia 2017
- Concerns with Long-Term Estrogen Exposure, Inconsistent Treatment Use, and Reduced Quality of Life in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy 2017
- Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms 2017
- Significant Improvement in Vaginal Epithelium with TX-004HR in Postmenopausal Women with Moderate-to-Severe Vulvar and Vaginal Atrophy (VVA) and Dyspareunia 2016
- TX-004HR Improves Vaginal Physiology and Dyspareunia with Negligible Systemic Absorption 2016
- TX-004HR Provides Robust Efficacy for Symptomatic Postmenopausal Vulvar and Vaginal Atrophy (VVA) while Providing Negligible to Very Low Systemic Absorption of Estradiol: Results of Clinical Phase 2 and 3 Trials 2016
- Effects of Ospemifene on Lipid and Coagulation Parameters in Postmenopausal Women 2015
- Effect of Ospemifene on Vasomotor Symptoms in Postmenopausal Women 2014
- Incidence of Endometrial Spotting and Bleeding during Continuous Combined Estrogen plus Progestin Therapy in Normotensive versus Hypertensive Postmenopausal Women 2014
- Ospemifene Improved The Severity of Vulvar and Vaginal Atrophy Symptoms In Postmenopausal Women In Phase 3 Randomized, Placebo-Controlled Trials 2014
- Responder Analysis of Ospemifene Treatment for Vulvar and Vaginal Atrophy in Postmenopausal Women in Phase 3 Randomized, Placebo-Controlled Trials 2014
- Safety of Oral Ospemifene in Phase 2/3 Placebo-controlled Clinical Trials 2013
- Vaginal and systemic cytokines in postmenopausal women with and without symptoms of vulvovaginal irritation 2013
- Cardiovascular, Cerebrovascular and Hepatic Safety of Desvenlafaxine Over 1 Year in Women With Vasomotor Symptoms Associated With Menopause 2011
- Is There Ever an Indication for Hormone Therapy in an Asymptomatic Postmenopausal Woman? 2011
- One-year Maintenance of Efficacy and Safety of Desvenlafaxine in Women With Vasomotor Symptoms Associated With Menopause 2011
- Safety and Tolerability of Bazedoxifene/Conjugated Estrogens in Postmenopausal Women: Findings From a 1-Year, Randomized, Placebo- and Active-controlled, Phase 3 Trial 2011
- Transdermal estradiol gel for the treatment of symptomatic postmenopausal women 2011
- High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom 2010
- Vaginal cytokines in postmenopausal women with symptoms of vulvovaginal irritation 2010
- Intravaginal DHEA, the Physiological and Highly Efficient Treatment of Vaginal Atrophy 2008
- Tailoring Progestogen Therapy for the Individual Patient 2008
- Clinical outcomes associated with new oral low-dose EPT 2007
- Microarray analysis of genes related with angiogenesis in human endometrial cells trated with delta 4-tibolone and medroxyprogesterone acetate 2005
- Influencing factors on women's attitudes toward hormone therapy acceptance for menopause treatment: a systematic review 2023
- The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review 2018
- Science of intracrinology in postmenopausal women 2017
- Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence 2015
- Recent advances help understand and improve the safety of menopausal therapies 2015
- Efficacy and tolerability of local estrogen therapy for urogenital atrophy 2010
- Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society 2008
- Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society 2007
Identity
International Standard Serial Number (ISSN)
- 1072-3714
Electronic International Standard Serial Number (EISSN)
- 1530-0374